March 26, 2020 / 12:15 PM / 11 days ago

BRIEF-Evox Therapeutics And Takeda Sign Multi-Target Rare Disease Collaboration

March 26 (Reuters) - Takeda Pharmaceutical Co Ltd:

* EVOX THERAPEUTICS AND TAKEDA SIGN MULTI-TARGET RARE DISEASE COLLABORATION

* EVOX THERAPEUTICS LTD - WILL BE ELIGIBLE TO RECEIVE UP TO $44 MILLION IN UPFRONT, NEAR-TERM MILESTONE PAYMENTS AND RESEARCH FUNDING

* EVOX THERAPEUTICS - IN TOTAL, CO ELIGIBLE TO RECEIVE APPROXIMATELY $882 MILLION IN UPFRONT, DEVELOPMENT, AND COMMERCIAL MILESTONE PAYMENTS FROM TAKEDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below